San Diego, Calif., October 31, 2017 – Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ lipid-mediated delivery […]
SAN DIEGO – October 31, 2017 – Synthetic Genomics, Inc. announced today that the company has entered into a collaboration with Ceva Santé Animale to utilize Synthetic Genomics’ next-generation synthetic RNA replicon platform to develop vaccines for livestock. The technology opens the door to more effective vaccines and therapeutics.
October 26, 2017 — Synthetic Genomics, Inc. is part of the recently funded DARPA Pandemic Prevention Platform (P3) program aimed at establishing a system capable of halting viral pandemics within 60 days. As part of the collaboration, led by Duke, Synthetic Genomics will contribute synthetic biology technologies to enable rapid delivery of anti-viral countermeasures.
SGI-DNA’s benchtop automated DNA printer to accelerate genomic research as part of VIB’s Technology Watch Initiative FLANDERS, BELGIUM AND SAN DIEGO, Aug. 22, 2017 – SGI-DNA Inc., a Synthetic Genomics Inc. (SGI) company, and VIB, a Belgian life science research institute, today announced that VIB will become the first institute in Europe to integrate the […]
Algae strain developed and modified by Synthetic Genomics more than doubled oil production Additional research and testing required before commercial application Results published in peer-reviewed journal Nature Biotechnology IRVING, Texas and LA JOLLA, Calif. – ExxonMobil and Synthetic Genomics Inc. today announced a breakthrough in joint research into advanced biofuels involving the modification of an […]
Customized suite to support Phase 1 study of Advaxis’ personalized cancer immunotherapy SAN DIEGO, June 1, 2017 — Synthetic Genomics, Inc. and Advaxis, Inc. (NASDAQ:ADXS) announced today that they have completed development and deployment of the first current good manufacturing practice (cGMP) synthetic biology facility for the production of synthetic DNA constructs. The cGMP suite […]
The first fully automated machine to convert digital code into functional biologics without human intervention creates entirely new avenues for precision medicine SAN DIEGO, May 29, 2017 — Synthetic Genomics, Inc. announced today the publication of a peer reviewed article describing the development and operation of its digital-to-biological converter (DBC) prototype that produced biologic compounds […]
LA JOLLA, Calif. – Synthetic Genomics, Inc. and ExxonMobil (NYSE: XOM) announced today that they have extended their agreement to conduct joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production. ExxonMobil and Synthetic Genomics have been jointly researching and developing oil from algae for […]
SAN DIEGO, Jan. 9, 2017 /PRNewswire/ — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble […]
SAN DIEGO, Jan. 5, 2017 – Synthetic Genomics, Inc., announced today that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics’ proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific […]